Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 2.2% - Should You Sell?

Key Points

• Hemogenyx Pharmaceuticals' shares experienced a decline of 2.2% during trading, with the stock closing at GBX 968 ($13.00).
• The company has a high debt-to-equity ratio of 90.87 and a market capitalization of £51.89 million.
• Hemogenyx Pharmaceuticals focuses on developing therapies for blood diseases and recently reported earnings of GBX (0.83) per share for the quarter.

Hemogenyx Pharmaceuticals Plc (LON:HEMO - Get Free Report)'s share price was down 2.2% during trading on Friday . The stock traded as low as GBX 946 ($12.70) and last traded at GBX 968 ($13.00). Approximately 22,713 shares traded hands during trading, a decline of 64% from the average daily volume of 63,164 shares. The stock had previously closed at GBX 990 ($13.29).

Hemogenyx Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 90.87, a current ratio of 4.38 and a quick ratio of 6.72. The company has a market capitalization of £51.89 million, a PE ratio of -419.20 and a beta of 3.14. The firm has a 50-day moving average of GBX 830.68 and a 200 day moving average of GBX 396.91.

Hemogenyx Pharmaceuticals (LON:HEMO - Get Free Report) last posted its earnings results on Tuesday, September 30th. The company reported GBX (0.83) earnings per share for the quarter.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.